Abnormal B Lymphocyte Activation and Function in Systemic Sclerosis

키워드

참고문헌 (65)

1. LeRoy EC, "Scleroderma (systemic sclerosis):classification, subsets and pathogenesis", J Rheumatol, 15, pp.202~205 (1988)
2. Furst DE, "Hypothesis for the pathogenesis of systemic sclerosis", J Rheumatol Suppl, 48, pp.53~57 (1997)
3. Yoshizaki A, "Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation", Ann Rheum Dis, 70, pp.194~200 (2011)
4. Yoshizaki A, "Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity", J Clin Immunol, 29, pp.180~189 (2009)
5. Okano Y, "Antinuclear antibody in systemic sclerosis (scleroderma)", Rheum Dis Clin North Am, 22, pp.709~735 (1996)
6. Hayakawa I, "Improvement of skin sclerosis after occurrence of anticentromere antibody in a patient with diffuse cutaneous systemic sclerosis", Clin Rheumatol, 23, pp.345~347 (2004)
7. Yoshizaki A, "Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling", Arthritis Rheum, 63, pp.3575~3585 (2011)
8. Sato S, "Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis", Mol Immunol, 41, pp.1123~1133 (2004)
9. Lipsky PE, "Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity", Nat Immunol, 2, pp.764~766 (2001)
10. Whitfield ML, "Systemic and cell type-specific gene expression patterns in scleroderma skin", Proc Natl Acad Sci U S A, 100, pp.12319~12324 (2003)
11. Goodnow CC, "Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires", Proc Natl Acad Sci U S A, 93, pp.2264~2271 (1996)
12. Tedder TF, "Introduction: response-regulators of B lymphocyte signaling thresholds provide a context for antigen receptor signal transduction", Semin Immunol, 10, pp.259~265 (1998)
13. Tedder TF, "The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity", Immunity, 6, pp.107~118 (1997)
14. Bolland S, "Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis", Immunity, 13, pp.277~285 (2000)
15. Majeti R, "An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity", Cell, 103, pp.1059~1070 (2000)
16. Pan C, "CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation", Immunity, 11, pp.495~506 (1999)
17. Inaoki M, "CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes", J Exp Med, 186, pp.1923~1931 (1997)
18. Sato S, "CD19regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity", J Immunol, 157, pp.4371~4378 (1996)
19. Sato S, "CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice", Immunity, 5, pp.551~562 (1996)
20. O'Keefe TL, "Hyperresponsive B cells in CD22-deficient mice", Science, 274, pp.798~801 (1996)
21. Painter CJ, "Specificities and V genes encoding monoclonal autoantibodies from viable motheaten mice", J Exp Med, 167, pp.1137~1153 (1988)
22. Tedder TF, "The CD19", CD21 signal transduction complex of B lymphocytes, 1994, pp.15, 437~442
23. Tedder TF, "The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system", Curr Dir Autoimmun, 8, pp.55~90 (2005)
24. Fujimoto M, "CD19regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification", Immunol Res, 22, pp.281~298 (2000)
25. Engel P, "Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19signal transduction molecule", Immunity, 3, pp.39~50 (1995)
26. Rickert RC, "Impairment of T-celldependent B-cell responses and B-1 cell development in CD19-deficient mice", Nature, 376, pp.352~355 (1995)
27. Sato S, "The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation", Proc Natl Acad Sci U S A, 92, pp.11558~11562 (1995)
28. Sato S, "CD19 expression levels regulate B lymphocyte development: human CD19restores normal function in mice lacking endogenous CD19", J Immunol, 158, pp.4662~4669 (1997)
29. Zhou LJ, "Tissue-specific expression of the human CD19gene in transgenic mice inhibits antigen-independent Blymphocyte development", Mol Cell Biol, 14, pp.3884~3894 (1994)
30. Sato S, "Quantitative genetic variation in CD19 expression correlates with autoimmunity", J Immunol, 165, pp.6635~6643 (2000)
31. Sato S, "Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells", Arthritis Rheum, 50, pp.1918~1927 (2004)
32. Asano N, "B Lymphocyte signaling established by the CD19", CD22 loop regulates autoimmunity in the tight-skin mouse, 2004, pp.165, 641~650
33. Famularo G, "Polyclonal B lymphocyte activation in progressive systemic sclerosis", J Clin Lab Immunol, 29, pp.59~63 (1989)
34. Fleischmajer R, "Cellular infiltrates in scleroderma skin", Arthritis Rheum, 20, pp.975~984 (1977)
35. Fujimoto M, "B lymphocytes and systemic sclerosis", Curr Opin Rheumatol, 17, pp.746~751 (2005)
36. Wang J, "Expression and function of Fas during differentiation and activation of B cells", Int Rev Immunol, 18, pp.367~379 (1999)
37. Siracusa LD, "A tandem duplication within the fibrillin 1gene is associated with the mouse tight skin mutation", Genome Res, 6, pp.300~313 (1996)
38. Saito S, "Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene", Mol Med, 6, pp.825~836 (2000)
39. Wallace VA, "A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice", Eur J Immunol, 24, pp.1463~1466 (1994)
40. Kodera T, "Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts", Proc Natl Acad Sci U S A, 99, pp.3800~3805 (2002)
41. Zhu H, "Polymorphisms of the TGF-beta1 promoter in tight skin (TSK) mice", Autoimmunity, 37, pp.51~55 (2004)
42. Saito E, "CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse", J Clin Invest, 109, pp.1453~1462 (2002)
43. Hasegawa M, "Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis", J Dermatol Sci, 39, pp.1~7 (2005)
44. Yamamoto T, "Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma", J Invest Dermatol, 112, pp.456~462 (1999)
45. Yamamoto T, "The bleomycin-induced scleroderma model:what have we learned for scleroderma pathogenesis?", Arch Dermatol Res, 297, pp.333~344 (2006)
46. Matsushita T, "BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice", J Invest Dermatol, 127, pp.2772~2780 (2007)
47. Hasegawa M, "B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis", Am J Pathol, 169, pp.954~966 (2006)
48. Arnett FC, "Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts", Arthritis Rheum, 44, pp.1359~1362 (2001)
49. Yoshizaki A, "CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma", Am J Pathol, 172, pp.1650~1663 (2008)
50. Janeway CA Jr, "Innate immune recognition", Annu Rev Immunol, 20, pp.197~216 (2002)
51. Marshak-Rothstein A, "Toll-like receptors in systemic autoimmune disease", Nat Rev Immunol, 6, pp.823~835 (2006)
52. Lotze MT, "High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal", Nat Rev Immunol, 5, pp.331~342 (2005)
53. Yoshizaki A, "Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity", J Rheumatol, 35, pp.1825~1829 (2008)
54. Rosen A, "Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease", Cell Death Differ, 6, pp.6~12 (1999)
55. Casiano CA, "Selective cleavage of nuclear autoantigens during CD95 (Fas", APO-1)-mediated T cell apoptosis, 1996, pp.184, 765~770
56. Sgonc R, "Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma", J Clin Invest, 98, pp.785~792 (1996)
57. Yamamoto T, "Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma", J Invest Dermatol, 122, pp.44~50 (2004)
58. Inghilleri S, "In situ assessment of oxidant and nitrogenic stress in bleomycin pulmonary fibrosis", Histochem Cell Biol, 125, pp.661~669 (2006)
59. Manoury B, "The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis", Respir Res, 6, pp.11~ (2005)
60. Yoshizaki A, "The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis", Arthritis Rheum, 63, pp.3086~3097 (2011)
61. Ogawa F, "Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis", Rheumatology (Oxford), 45, pp.815~818 (2006)
62. Simonini G, "Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis", Toxicology, 155, pp.1~15 (2000)
63. Mendoza G, "Inhibitory effects of different antioxidants on hyaluronan depolymerization", Carbohydr Res, 342, pp.96~102 (2007)
64. Freitas JP, "Guerra Rodrigo F. Hyaluronic acid in progressive systemic sclerosis", Dermatology, 192, pp.46~49 (1996)
65. Neudecker BA, "Aberrant serum hyaluronan and hyaluronidase levels in scleroderma", Br J Dermatol, 150, pp.469~476 (2004)

관련 논문AI추천